Biotinylated Human B7-H4 Protein, Avitag™,His Tag (recommended for biopanning) (MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
B74-H82E2-25ug
$380.00
B74-H82E2-200ug
$1645.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    B7-H4, VTCN1, B7S1, B7h.5

  • Source

    Biotinylated Human B7-H4 Protein, Avitag,His Tag (B74-H82E2) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Ala 258 (Accession # NP_078902).

    Predicted N-terminus: Phe 29

    Request for sequence
  • Molecular Characterization

    B7-H4 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.

    The protein has a calculated MW of 28 kDa. The protein migrates as 43-57 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Application

    B74-H82E2 works best for experiments that test the binding between B7-H4 and candidate antibodies, such as biopanning and other relevant assays.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    B7-H4 SDS-PAGE

    Biotinylated Human B7-H4 Protein, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    B7-H4 SEC-MALS

    The purity of Biotinylated Human B7-H4 Protein, Avitag,His Tag (Cat. No. B74-H82E2) is more than 85% and the molecular weight of this protein is around 40-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     B7-H4 ELISA

    Immobilized Anti-Human B7-H4 MAb, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human B7-H4 Protein, Avitag,His Tag (Cat. No. B74-H82E2) with a linear range of 3-48 ng/mL (QC tested).

    Protocol

ユーザーレビュー
コメントを投稿

  • 1***12019-11-16
    いいね
    We purchased total of 600ug of this biotin-labeled antigen for liquid phase panning and antibody screening of affinity maturation. This antigen has good stability, high quality, and high repeatability for each experiment. Using this antigen, we screened high-affinity antibodies against this target. And using this antigen for screening of affinity maturation, we obtained antibodies with 10-times increased affinity. I highly recommended this product.

バックグランド

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    V-set domain-containing T-cell activation inhibitor 1

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    11 詳細

  • 最新の開発ステージ:

    Phase 3 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8